🇺🇸 FDA
Pipeline program

Secukinumab s.c. injection

CAIN457A02001B

Approved mab active

Quick answer

Secukinumab s.c. injection for Autoimmunity, Inflammation is a Approved program (mab) at Novartis Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Pharmaceuticals
Indication
Autoimmunity, Inflammation
Phase
Approved
Modality
mab
Status
active

Clinical trials